OVERVIEW OF ANTI-ANGINAL DRUGS

Angina pectoris, characterized by chest pain due to myocardial ischemia, is a common manifestation of coronary artery disease. Anti-anginal drugs are essential in managing this condition by improving oxygen delivery to the heart or reducing myocardial oxygen demand. These agents are broadly classified into nitrates, beta-blockers, calcium channel blockers, and newer agents like ranolazine, ivabradine, and nicorandil. Nitrates, such as nitroglycerin, provide rapid relief by vasodilation, whereas beta-blockers and calcium channel blockers help prevent angina by controlling heart rate and reducing afterload. Emerging therapies target metabolic pathways and offer options for patients with refractory angina. This overview highlights the pharmacological mechanisms, clinical uses, and advancements in anti-anginal drug therapy, emphasizing the importance of personalized treatment strategies to enhance patient outcome[1].